Tyrosine kinase inhibitors (TKIs) of the EGF receptor (EGFR) have provided a significant improvement in the disease outcome of nonsmall cell lung cancer (NSCLC). Unfortunately, resistance to these agents frequently occurs, and it is often related to the activation of the Hedgehog (Hh) and MET signaling cascades driving the epithelial-to-mesenchymal transition (EMT). Because the concomitant inhibition of both Hh and MET pathways restores the sensitivity to anti-EGFR drugs, here we aimed at discovering the first compounds that block simultaneously MET and SMO. By using an “in silico drug repurposing” approach and by validating our predictions both in vitro and in vivo, we identified a set of compounds with the desired dual inhibitory activity and enhanced antiproliferative activity on EGFR TKI-resistant NSCLC. The identification of the known MET TKIs, glesatinib and foretinib, as negative modulators of the Hh pathway, widens their application in the context of NSCLC

Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer / Morgillo, Floriana; Amendola, Giorgio; Della Corte, Carminia Maria; Giacomelli, Chiara; Botta, Lorenzo; Di Maro, Salvatore; Messere, Anna; Ciaramella, Vincenza; Taliani, Sabrina; Marinelli, Luciana; Trincavelli, Maria Letizia; Martini, Claudia; Novellino, Ettore; Ciardiello, Fortunato; Cosconati, Sandro. - In: JOURNAL OF MEDICINAL CHEMISTRY. - ISSN 0022-2623. - 60:17(2017), pp. 7447-7458. [10.1021/acs.jmedchem.7b00794]

Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer

BOTTA, LORENZO;Di Maro, Salvatore;Messere, Anna;Marinelli, Luciana;Novellino, Ettore;Ciardiello, Fortunato;Cosconati, Sandro
2017

Abstract

Tyrosine kinase inhibitors (TKIs) of the EGF receptor (EGFR) have provided a significant improvement in the disease outcome of nonsmall cell lung cancer (NSCLC). Unfortunately, resistance to these agents frequently occurs, and it is often related to the activation of the Hedgehog (Hh) and MET signaling cascades driving the epithelial-to-mesenchymal transition (EMT). Because the concomitant inhibition of both Hh and MET pathways restores the sensitivity to anti-EGFR drugs, here we aimed at discovering the first compounds that block simultaneously MET and SMO. By using an “in silico drug repurposing” approach and by validating our predictions both in vitro and in vivo, we identified a set of compounds with the desired dual inhibitory activity and enhanced antiproliferative activity on EGFR TKI-resistant NSCLC. The identification of the known MET TKIs, glesatinib and foretinib, as negative modulators of the Hh pathway, widens their application in the context of NSCLC
2017
Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer / Morgillo, Floriana; Amendola, Giorgio; Della Corte, Carminia Maria; Giacomelli, Chiara; Botta, Lorenzo; Di Maro, Salvatore; Messere, Anna; Ciaramella, Vincenza; Taliani, Sabrina; Marinelli, Luciana; Trincavelli, Maria Letizia; Martini, Claudia; Novellino, Ettore; Ciardiello, Fortunato; Cosconati, Sandro. - In: JOURNAL OF MEDICINAL CHEMISTRY. - ISSN 0022-2623. - 60:17(2017), pp. 7447-7458. [10.1021/acs.jmedchem.7b00794]
File in questo prodotto:
File Dimensione Formato  
acs.jmedchem.7b00794.pdf

accesso aperto

Tipologia: Documento in Post-print
Licenza: Dominio pubblico
Dimensione 4.58 MB
Formato Adobe PDF
4.58 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/700355
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 24
  • ???jsp.display-item.citation.isi??? 20
social impact